Growth

47 drugs in development·30 companies·1 clinical trial

Drug Pipeline by Phase

Approved(19)

Drug	Company
Alimta®	ELI LILLY & Co (LLY)
alymsys	Amneal Pharmaceuticals, Inc. (AMRX)
Cyramza	ELI LILLY & Co (LLY)
Cyramza®	ELI LILLY & Co (LLY)
fulphila	Mylan II B.V. (MYL)
hydrascalp powered by keravive	The Beauty Health Company (SKIN)
ibrance	PFIZER INC (PFE)
kisqali femara co-pack	Novartis AG (NVS)
ngenla	OPKO HEALTH, INC. (OPK)
ngenla	PFIZER INC (PFE)
nypozi	GT Biopharma, Inc. (GTBP)
portrazza	ELI LILLY & Co (LLY)
skytrofa	Ascendis Pharma A/S (ASND)
somatrogon	OPKO HEALTH, INC. (OPK)
trodelvy	Immunome Inc. (IMNM)
tykerb	Novartis AG (NVS)
udenyca	Coherus Oncology, Inc. (CHRS)
vizimpro	PFIZER INC (PFE)
zaltrap	Sanofi (SNY)

Phase 3(11)

Drug	Company
gb06	TC BioPharm (Holdings) plc (TCBWF)
norditropin	Novo Nordisk A/S (NVO)
norditropin flexpro	Novo Nordisk A/S (NVO)
norditropin flexpro pen	Novo Nordisk A/S (NVO)
norditropinflexprotm	TC BioPharm (Holdings) plc (TCBWF)
Plinabulin	BeyondSpring Inc. (BYSI)
rhIGF-I/rhIGFBP-3	INSMED Inc (INSM)
RLY-2608	Relay Therapeutics, Inc. (RLAY)
somapacitan	Novo Nordisk A/S (NVO)
somatropin	OPKO HEALTH, INC. (OPK)
somatropin	GH Research PLC (GHRS)

Phase 2(6)

Drug	Company
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
Goserelin	ENANTA PHARMACEUTICALS INC (ENTA)
Iparomlimab and Tuvonralimab	Merus N.V. (MRUS)
lum-201	LUMOS PHARMA, INC. (NLNK)
mod-4023	OPKO HEALTH, INC. (OPK)
rhgh norditropin pen	LUMOS PHARMA, INC. (NLNK)

Phase 1(2)

Drug	Company
CT-0525	Carisma Therapeutics Inc. (CARM)
EOS-215	iTeos Therapeutics, Inc. (ITOS)

Preclinical(4)

Drug	Company
Additional discovery and early preclinical programs	Scholar Rock Holding Corp (SRRK)
myostatin x activin a bispecific antibody	iBio, Inc. (IBIO)
SBI-183	AXIM BIOTECHNOLOGIES, INC. (AXIM)
SPX-1009	AXIM BIOTECHNOLOGIES, INC. (AXIM)

Unknown(2)

Drug	Company
Cell Rejuven™	BIOADAPTIVES, INC. (BDPT)
Quiescin Sulfhydryl Oxidase 1 (QSOX1) license	AXIM BIOTECHNOLOGIES, INC. (AXIM)

Phase 1/Phase 2(2)

Drug	Company
ATR-04	Azitra, Inc. (AZTR)
miransertib	ARQULE INC (ARQL)

Phase 4(1)

Drug	Company
Alpelisib	Novartis AG (NVS)

BioSniper tracks 47 drugs in development for Growth across 30 companies.

There are 1 clinical trial targeting Growth tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.